Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tropomyosin receptor kinases A, B, and C (TrkA, TrkB, TrkC) are a family of single-pass transmembrane receptor tyrosine kinases that serve as high-affinity receptors for neurotrophins. Each subtype has a preferred ligand: TrkA binds nerve growth factor (NGF), TrkB binds brain-derived neurotrophic factor (BDNF) and neurotrophin‑4 (NT‑4), while TrkC primarily binds neurotrophin‑3 (NT‑3). Upon ligand binding, these receptors dimerize and autophosphorylate their intracellular domains, activating multiple downstream signaling cascades including Ras/MAPK and PI3K/Akt pathways. These signals regulate neuronal survival, differentiation, synaptic plasticity, cell proliferation, motility, apoptosis avoidance—and play critical roles in both development and maintenance of the nervous system. Genetic alterations such as fusions or mutations involving the genes encoding these receptors (NTRK1, NTRK2, NTRK3) have been implicated in various cancers by driving constitutive activation independent of ligand binding. As a result they are important therapeutic targets; several selective inhibitors have been developed specifically targeting tumors harboring such alterations. Beyond oncology they are also involved in rare congenital neurological disorders when mutated or dysfunctional.
Inhibition of the intracellular tyrosine kinase domain to block downstream neurotrophin signaling pathways such as Ras/MAPK and PI3K/Akt
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tropomyosin receptor kinase A, B, and C (TrkA, TrkB, TrkC).